PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Bid/Ask 13:43:18 2024-06-10 EDT | After market 14:43:56 | |||
| 2.23 EUR | -1.33% |
|
2.225 | -0.22% |
| Current month | -29.15% | ||
| 1 month | -38.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 2.23 | -1.33% |
| 24-06-07 | 2.26 | -7.76% |
| 24-06-06 | 2.45 | -14.63% |
| 24-06-04 | 2.87 | -7.72% |
| 24-06-03 | 3.11 | -2.51% |
Real-time Boerse Frankfurt Warrants
Last update June 10, 2024 at 01:43 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XAZ |
| ISIN | DE000VD1XAZ6 |
| Date issued | 2024-03-08 |
| Strike | 1,158 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.28 € |
|---|---|
| Lowest since issue | 2.23 € |
| Spread | 0.07 € |
| Spread % | 3.08% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.54%
- Stock Market
- Certificates
- Certificat
